NEBA encourages legislators and other key officials at the local, state, and federal level to adopt policies that:
The New England Biotech Association urges policy makers in New England to oppose measures harmful to the biotech industry such as: price controls of breakthrough medicines; onerous restrictions on educational & marketing practices of biotechnology companies; and risky importation of medicines not regulated and approved by the FDA.
2015/2016 Public Policy Priorities
Medicine Pricing "Transparency"
Take back/Pharmaceuticals in the Environment